Press release
Multi-Infarct Dementia (MID) Market - Emergence of Advanced Technologies and growth opportunities by 2023
Download Exclusive Sample of this Report: http://bit.ly/2fCJlBU
According to the National Institutes of Health, multi-infarct dementia is the second leading form of dementia, accounting for up to 20% of all cases dementia cases in people above age 65. An integrative approach to diagnosis of multi-infarct dementia is recommended which involves symptoms, medical history, health and lifestyle and certain cognitive tests in order to assess person’s cognitive ability. A specialist doctor may look for blood pressure, cholesterol levels, an electrocardiograph, etc to support a diagnosis of multi-infarct dementia. Imaging techniques such as computed tomography (CT scan) or a magnetic resonance imaging scan (MRI)
Presently, there is no treatment available to reverse the damage of brain cells that has been occurred due to stroke. Therefore, the multi-infarct dementia or vascular dementia therapy largely focuses on prevention of future strokes through controlling or avoiding conditions and diseases which increase the risk of stroke. The pharmacological treatment for multi-infarct dementia (MID) includes cholinesterase inhibitors (ChEIs) such as donepezil, galantamine, and rivastigmine. Rivastigmine is a second generation cholinesterase inhibitor with the capacity to inhibit both acetylcholinesterase and butyrylcholinesterase.
Other promising pharmacological medications prescribed for management of multi-infarct dementia include memantine, nimodipine, hydergine, folic acid and Cytidine 5′-Diphosphocholine (CDP-choline). Other classes of drugs utilized to treat multi-infarct dementia include selective serotonin reuptake inhibitors (SSRIs), calcium channel blockers (CCBs) and angiotensin-converting-enzyme inhibitors (ACE inhibitors).
Non-pharmacological approaches are equally important in the management of patients with multi-infarct dementia. The prognosis of multi-infarct dementia is generally poor and the 5-year survival rate is very less compared to other dementia. Moreover, unlike Alzheimer’s disease in which people are susceptible to infections, multi-infarct dementia may directly result into death due to probability of low supply of blood to brain. Despite the evidence that people with multi-infarct dementia improve over time, the condition can become abruptly worse after occurrence of silent strokes.
Geographically, the global multi-infarct dementia (MID) market can be segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World. Multi-infarct dementia is second most common type of dementia in North America and Europe, while it is the most common type of dementia in Asia and other parts of the world. For instance, it accounts for more than 50% of dementia cases in Japan.
Browse Research Report: http://bit.ly/2eNleSb
The prevalence of multi-infarct dementia (MID) is expected to rise drastically in the near future given the exponential rise in geriatric population of the world. Therefore, the global multi-infarct dementia (MID) market is expected to grow rapidly in the developed nations such as the U.S., Canada, Germany, France, and Japan where there is enormous rise in the elderly people.
Some of the key players in the global multi-infarct dementia (MID) market include Eisai, Inc., Pfizer, Inc., Novartis Pharmaceutical Corporation, Janssen Pharmaceuticals, Inc., and Forest Laboratories, Inc.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Multi-Infarct Dementia (MID) Market - Emergence of Advanced Technologies and growth opportunities by 2023 here
News-ID: 384585 • Views: …
More Releases from TMR - Research Reports
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during…
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the…
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016.
The global dental membrane and bone graft substitutes market is expected to…
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period.
By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment…
More Releases for MID
Mid-IR Laser Crystal Market
Mid-IR Laser Crystal Market Overview
For mid-infrared (and partly also terahertz) generation, one requires crystal materials with a transparency range extending far into the infrared spectral region. The most important of these media are zinc germanium diphosphide (ZGP, ZnGeP2), silver gallium sulfide and selenide (AgGaS2 and AgGaSe2), gallium selenide (GaSe), and cadmium selenide (CdSe). Gallium arsenide (GaAs) has also become useful for mid-infrared applications, since it is possible to obtain quasi-phase…
Mid-Michigan Legal & Consulting Offers Top-Notch Legal Services throughout Mid a …
Mid-Michigan Legal & Consulting, led by Bethany Gomez, RN, Attorney, is proud to offer a wide array of legal services throughout Mid and Southeast Michigan. With a comprehensive range of services including estate planning/probate [https://midmichlegal.com/], personal injury, litigation support, business/corporate planning, social security disability, and mediation services, Mid-Michigan Legal & Consulting is dedicated to providing exceptional legal representation and guidance to their clients.
Bethany Gomez, RN, Attorney, brings a unique perspective…
Mid Infrared Lasers Market Technological Advancements 2023
Mid-infrared lasers emit laser like beams and have wavelength ranging from 3 μm to 8 μm. These lasers may either contain some shorter-wavelength laser or a mid-infrared (mid-IR) combined with means required for nonlinear frequency conversion.
Mid-infrared lasers are in great demand for variety of applications including polymer and plastic processing, pumping optical parametric oscillators (OPOs), free space communications, remote sensing, laser scalpel, non-invasive medical diagnosis, and spectroscopy.
Various defense…
Panthera Technologies Expands Mid-Atlantic Presence
Baltimore, MD – March 23, 2016 - Panthera Technologies, a leading Managed Service Provider, Outsource IT Operations and Compliance as a Service firm, is proud to announce the expansion of their Corporate Headquarters based in Owings Mills, Maryland.
In partnership with BECO Management Inc. Panthera Technologies more than doubles their current corporate footprint in Owings Mills. “We have had a true partnership with BECO and their Management team over the…
Engage PEO Forms Mid-Market Division
Group Created to Address Growing Demand from Large Employers For Strategic HR and Benefits Services.
Fort Lauderdale, Fla. -- Engage PEO, a leading professional employer organization providing HR outsourcing solutions to small and mid-sized businesses across the U.S., today announced the formation of a new division dedicated to serve the needs of employers with more than 500 employees. The Mid-Market division was created in response to the growing demand from larger…
Rosendin Electric Expands Mid-Atlantic Operations
Newest Regional Office in Baltimore Brings BIM, Design-Build, and Data Center Expertise to Construction Projects in Maryland, Delaware, and Pennsylvania.
Baltimore (April 10, 2014) -- Rosendin Electric (http://www.rosendin.com), the nation's largest private electrical contractor and an employee-owned company, announced the expansion of its East Coast Operations with the opening of an office in Baltimore, Maryland.
Headquartered in San Jose, California, Rosendin Electric serves commercial, business and government clients throughout the country. This…
